Integrin-mediated drug delivery in cancer and cardiovascular diseases with peptide-functionalized nanoparticles

Current Medicinal Chemistry

Volumn 19, Issue 19, 2012, Pages 3128-3151

  Arosio, D ^a   Casagrande, C ^a   Manzoni, L ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Cancer; Cardiovascular diseases; Drug delivery; Integrins; Nanoparticles; Peptides; RGD

Indexed keywords

ABCIXIMAB; CILENGITIDE; COMBRETASTATIN A4; DOXORUBICIN; EFALIZUMAB; EPTIFIBATIDE; ETARACIZUMAB; FIRATEGRAST; FLUOROURACIL; INTEGRIN; MITOXANTRONE; N ACETYLCOLCHINOL PHOSPHATE; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; NANOPARTICLE; NATALIZUMAB; PACLITAXEL; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TIROFIBAN; VALATEGRAST; VERY LATE ACTIVATION ANTIGEN 4; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN RECEPTOR; VOLOCIXIMAB;

ARTERY THROMBOSIS; ATHEROSCLEROSIS; BLOOD BRAIN BARRIER; BREAST CANCER; CANCER CELL; CARDIOVASCULAR DISEASE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG STRUCTURE; GLIOBLASTOMA; GLIOMA; HUMAN; MELANOMA; MICELLE; MICROBUBBLE; NEOPLASM; NONHUMAN; OVARY CANCER; PARTICLE SIZE; PROSTATE CANCER; REVIEW;

ANIMALS; CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; INTEGRINS; NANOPARTICLES; NEOPLASMS;

EID: 84863638984     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712800784748     Document Type: Review

References (288)

1. Riehemann, K.; Schneider, S.W.; Luger, T.A.; Godin, B.; Ferrari, M.; Fuchs, H. Nanomedicine-challenge and perspectives. Angew. Chem. Int. Ed. Engl., 2009, 48, 872-897.
2. Caruthers, S.D.; Wickline, S.A.; Lanza, G.M. Nanotechnological applications in medicine. Curr.Opin. Biotechnol., 2007, 18, 26-30.
3. Moghimi, S.M.; Hunter, A.C.; Murray, J.C. Nanomedicine: current status and future prospects. FASEB J., 2005, 19, 311-330.
4. Jiang, W.; Kim, B.Y.S.; Rutka, J.T.; Chan, W.C.W. Advances and challenges of nanotechnology-based drug delivery systems. Expert Opin. Drug Deliv., 2007, 4, 621-633.
5. Emerich, D.F.; Thanos, C.G. Targeted nanoparticle-based drug delivery and diagnosis. J. Drug Target., 2007; 15(3): 163-183.
6. Kim, D.K.; Dobson, J. Nanomedicine for targeted drug delivery. J. Mater. Chem., 2009, 19, 6294-6307.
7. Ferrari, M. Cancer nanotechnologies: opportunity and challenges. Nat. Rev. Cancer, 2005, 5, 161-171.
8. Peer, D.; Karp, J.M.; Hong, S.; Farokhzad, O.C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol., 2007, 2, 751-760.
9. Cuenca, A.G.; Jiang, H.; Hochwald, S.N.; Delano, M.; Cance, W.G.; Grobmyer, S.R. Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer, 2006, 107, 459-466.
10. Haley, B.; Frenkel, E. Nanoparticles for drug delivery in cancer treatment. Urol. Oncol., 2008, 26, 57-64.
11. Liu, Y.; Miyoshi, H.; Nakamura, M. Nanomedicine for drug delivery and imaging: a promising avenue for cancer herapy and diagnosis using targeted functional nanoparticles. Int. J. Cancer, 2007, 120, 2527-2537.
12. Byrne, J.D.; Betancourt, T.; Brannon-Peppas, L. Active targeting schemes for nanoparticle systems in cancer therapeutics, Adv. Drug Deliv. Rev., 2008, 60, 1615-1626.
13. Gindy, M.E.; Prud'homme, R.K. Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy. Expert Opin. Drug Deliv., 2009, 6, 865-878.
14. Wickline, S.A.; Neubauer, A.M.; Winter, P.M.; Caruthers, S.D.; Lanza, G.M. Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. J. Magn. Reson. Imaging, 2007, 25, 667-680.
15. McCarthy, J.R. Multifunctional agents for concurrent imaging and therapy in cardiovascular disease, Adv. Drug Deliv. Rev., 2010, 62, 1023-1030.
16. Godin, B.; Sakamoto, J.H.; Serda, R.E.; Grattoni, A.; Bouamrani, A.; Ferrari, M. Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends Pharmacol. Sci., 2010, 31, 199-205.
17. Fitzgerald, K.T.; Holladay, CA.; McCarthy, C.; Power, K.A.; Pandit, A.; Gallagher, W.M. Standardization of models and methods used to assess nanoparticles in cardiovascular applications. Small, 2011, 7, 705-717.
18. Giancotti, F.G.; Ruoslahti, E. Integrin signaling. Science, 1999, 285, 1028-1032.
19. Hynes, R.O. Integrins: bidirectional, allosteric signaling machines. Cell, 2002, 110, 673-687.
20. Takada, Y.; Ye, X.; Simon, S. The integrins. Genome Biol., 2007. 8, 215.
21. Barczyk, M; Carracedo, S.; Gullberg, D. Integrins. Cell Tissue Res., 2010, 339, 269-280.
22. Humphries, M.J. Integrin structure. Biochemical Soc. Trans., 2000, 28, 311-339.
23. Humphries, M.J.; McEwan, P.A.; Barton, S.J.; Buckley, Bella, J.; Mould, A.P. Integrin structure: heady advances in ligand binding, but activation still makes the knees wobble. Trends Biochem. Sci., 2003, 28, 313-320.
24. Arnaout, M.A.; Mahalingam, B.; Xiong, J.P. Integrin structure, allostery, and bidirectional signaling. Annu. Rev. Cell Dev. Biol., 2005, 21, 381-410.
25. Xiao, T., Takagi, J.; Coller, B.S.; Wang, J.H.; Springer, T.A. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature, 2004, 432, 59-67.
26. Ruoslahti, E.; Pierschbacher, M.D. New perspectives in cell adhesion: RGD and integrins. Science, 1987, 238, 491-497.
27. Cox, D.; Brennan, M.; Moran, N. Integrins as therapeuthic targets: lessons and opportunities. Nat. Rev. Drug Discov., 2010, 9, 804-820.
28. Desgrosellier, J.S.; Cheresh, D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer, 2010. 10, 9-22.
29. Yusuf-Makangiasar, H.; Anderson, M.E.; Yakovleva, T.V.; Murray, J.S.; Siahaan, T.J. Inhibition of LFA.1/ICAM1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune disease. Medicinal Res. Rev., 2002, 22, 146-167.
30. Wang, Z., Chui, W.K.; Ho, P.C. Integrin targeted drug and gene delivery. Expert Opin. Drug Deliv., 2010, 7, 159-171.
31. Dunehoo, A.L.; Anderson, M.; Majumdar, S.; Kobayashi, N.; Berkland, C.; Siahaan, T.J. Cell adhesion molecules for targeted drug delivery. J. Pharm. Science, 2006, 95, 1856-1872.
32. Caruthers, S.D.; Cyrus, T.; Winter, P.M.; Wickline, S.A.; Lanza, G.M. Anti-angiogenic perfluorocarbon nanoparticles for diagnosis and treatment of atherosclerosis. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2009, 1, 311-323.
33. Carmeliet, P. Angiogenesis in life, disease and medicine. Nature, 2005, 438, 932-936.
34. Avraamides, C.J.; Garmy-Susini, B.; Varner, J.A. Integrins in angiogenesis and lymphangiogenesis. Nat. Rev. Cancer, 2008, 8, 604-617.
35. Alghisi, G.C.; Rüegg, C. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. Endothelium, 2006, 13, 113-135.
36. Ding, Q.; Stewart, J.; Olman, M.A.; Klobe, M.R.; Gladson, C.L. The pattern of enhancement of Src kinase activity on platelet-derived growth factor stimulation of glioblastoma cells is affected by the integrin engaged. J. Biol. Chem., 2003, 278, 39882-39891.
37. Kuphal, S.; Bauer, R.; Bosserhoff, A.K. Integrin signaling in malignant melanoma. Cancer Metastasis Rev., 2005, 24, 195-222.
38. Beck, V.; Herold, H.; Benge, A.; Luber, B.; Hutzler, P.; Tschesche, H.; Kessler, H.; Schmitt, M.; Geppert, H.G.; Reuning, U. ADAM15 decreases integrin alphavbeta3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion. Int. J. Biochem. Cell. Biol., 2005, 37, 590-603.
39. Chen, X.; Park, R.; Tohme, M.; Shahinian, A.H.; Bading, J.R.; Conti, P.S. MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F-and 64Cu-labeled RGD peptide. Bioconjugate Chem., 2004, 15, 41-49.
40. Mestas, J.; Ley, K. Monocyte-endothelial cell interactions in the development of atherosclerosis. Trends Cardiovasc. Med., 2008, 18, 228-232.
41. Lu, X.; Lu, D.; Scully, M.F.; Kakkar, V.V. The role of integrin-mediated cell adhesion in atherosclerosis: pathophysiology and clinical opportunities. Curr. Pharm. Des., 2008, 14, 2140-2158.
42. Cyrus, T.; Zhang, H.; Allen, J.S.; Williams, T.A.; Hu, G.; Caruthers, S.D.; Wickline, S.A.; Lanza, G.M. Intramural delivery of rapamycin with alphavbeta3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 820-826.
43. Hutchinson, J.H.; Halczenko, W.; Brashear, K.M.; Breslin, M.J.; Coleman, P.J.; Duong le, T.; Fernandez-Metzler, C.; Gentile, M.A.; Fisher, J.E.; Hartman, G.D.; Huff, J.R.; Kimmel, D.B.; Leu, C.T.; Meissner, R.S.; Merkle, K.; Nagy, R.; Pennypacker, B.; Perkins, J.J.; Prueksaritanont, T.; Rodan, G.A.; Varga, S.L.; Wesolowski, G.A.; Zartman, A.E.; Rodan, S.B.; Duggan, M.E. Nonpeptide αvβ3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. J. Med. Chem., 2003, 46, 4790-4798.
44. Livant, D.L.; Brabec, R.K.; Pienta, K.J.; Allen, D.L.; Kurachi, K.; Markwart, S.; Upadhyaya, A. Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res., 2000, 60, 309-320.
45. Nieswandt, B.; Pleines, I.; Bender, M. Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke. J. Thromb. Haemost., 2011, 1, 92-104.
46. Rosove, M.H. Platelet glycoprotein IIb/IIIa inhibitors. Best Pract. Res. Clin. Haematol., 2004, 17, 65-76.
47. Rice, G.P.; Hartung, H.P.; Calabresi, P.A. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology, 2005, 64, 1336-1342.
48. Yonekawa, K.; Harlan, J.M. Targeting leucocyte integrins in human diseases, J. Leukoc. Biol., 2005, 7, 129-140.
49. Davenport, R.J.; Munday, J.R. Alpha4 integrin antagonism-an effective approach for the treatment of inflammatory disease? Drug Discov. Today, 2007, 12, 569-575.
50. Merched, A.; Tollefson, K.; Chan, L. Beta2 integrins modulate the initiation and progression of atherosclerosis in low-density lipoprotein receptor knockout mice. Cardiovasc. Res., 2010, 85, 853-863.
51. Nahrendorf, M.; Jaffer, F.A.; Kelly, K.A.; Sosnovik, D.E.; Aikawa, E.; Libby, P.; Weissleder, R. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation, 2006, 114, 1504-1511.
52. Akhtar, A.M.; Schneider, J.E.; Chapman, S.J.; Jefferson, A.; Digby, J.E.; Mankia, K.; Chen, Y.; McAteer, M.A.; Wood, K.J.; Choudhury, R.P. In vivo quantification of VCAM-1 expression in renal ischemia reperfusion injury using non-invasive magnetic resonance molecular imaging. PLoS One, 2010, 5, e12800.
53. Hoyte, L.C.; Brooks, K.J.; Nagel, S.; Akhtar, A.; Chen, R.; Mardiguian, S.; McAteer, M.A.; Anthony, D.C.; Choudhury, R.P.; Buchan, A.M.; Sibson, N.R. Molecular magnetic resonance imaging of acute vascular cell adhesion molecule-1 expression in a mouse model of cerebral ischemia. J. Cereb. Blood Flow Metab., 2010, 30, 1178-1187.
54. Duong, L.T.; Rodan, G.A. Integrin-mediated signaling in the regulation of osteoclast adhesion and activation. Front. Biosci., 1998, 3, d757-d768.
55. Mizejewski, G.J. Role of integrins in cancer: survey of expression patterns. Proc. Soc. Exp. Biol. Med., 1999, 222, 124-138.
56. Kren, A., Baeriswyl, V.; Lehembre, F.; Wunderlin, C.; Strittmatter, K.; Antoniadis, H.; Fässler, R.; Cavallaro, U.; Christofori, G. Increased tumor cell dissemination and cellular senescence in the absence of beta1-integrin function. EMBO J., 2007, 26, 2832-2842.
57. Zutter, M.M., Santoro, S.A.; Staatz, W.D.; Tsung, Y.L. Re-expression of the alpha 2 beta 1 integrin abrogates the malignant phenotype of breast carcinoma cells. Proc. Natl. Acad. Sci. U S A, 1995, 92, 7411-7415.
58. Carmeliet, P.; Jain, R.K. Angiogenesis in cancer and other diseases. Nature, 2000, 407, 249-257.
59. Ribatti, D. The contribution of Harold F. Dvorak to the study of tumor angiogenesis and stroma generation mechanisms. Endothelium, 2007, 14, 131-135.
60. Friedlander, M.; Brooks, P.C.; Shaffer, R.W.; Kincaid, C.M.; Varner, J.A.; Cheresh, D.A. Definition of two angiogenic pathways by distinct alpha v integrins. Science, 1995, 270, 1500-1502.
61. Brooks, P.C.; Clark, R.A.; Cheresh, D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science, 1994, 264, 569-571.
62. Brooks, P.C.; Montgomery, A.M.; Rosenfeld, M.; Reisfeld, R.A.; Hu, T.; Klier, G.; Cheresh, D.A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 1994, 79(7), 1157-1164.
63. Laurence, N.; Engelse, M.A.; Jungerius, C.; Löwik, C.W.; van Hinsbergh, V.W.; Koolwijk, P. Single and combined effects of alphaVbeta3 and alpha5beta1 integrins on capillary tube formation in a human fibrinous matrix. Angiogenesis, 2009, 12, 275-285.
64. Miles, F.L.; Pruitt, F.L.; van Golen, K.L.; Cooper, C.R. Stepping out of the flow: capillary extravasation in cancer metastasis. Clin. Exp. Metastasis., 2008, 25, 305-324.
65. Huo, Y.; Ley, K. Adhesion molecules and atherogenesis. Acta Physiol. Scand., 2001, 173, 35-43.
66. Kakkar, A.K.; Lefer, D.J. Leukocyte and endothelial adhesion molecule studies in knockout mice. Curr. Opin. Pharmacol., 2004, 4, 154-158.
67. Kelly, K.A.; Allport, J.R.; Tsourkas, A.; Shinde-Patil, V.R.; Josephson, L.; Weissleder, R. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ. Res., 2005, 96, 327-336.
68. Nahrendorf, M.; Keliher, E.; Panizzi, P.; Zhang, H.; Hembrador, S.; Figueiredo, J.L.; Aikawa, E.; Kelly, K.; Libby, P.; Weissleder, R. 18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis. JACC Cardiovasc. Imaging, 2009, 2, 1213-1222.
69. Millard, M.; Odde, S.; Neamati, N. Integrin Targeted Therapeutics, Theranostics, 2011, 1, 154-188.
70. Xiong, J.P.; Stehle, T.; Diefenbach, B.; Zhang, R.; Dunker, R.; Scott, D.L.; Joachimiak, A.; Goodman, S.L.; Arnaout, M.A. Crystal structure of the extracellular segment of integrin alpha Vbeta3. Science, 2001, 294, 339-345.
71. Xiong, J.P.; Stehle, T.; Zhang, R.; Joachimiak, A.; Frech, M.; Goodman, S.L.; Arnaout, M.A. Crystal structure of the extracellular segment of integrin alphaV beta3 in complex with an Arg-Gly-Asp ligand. Science, 2002, 256, 151-155.
72. Ruoslahti, E. RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol., 1996, 12, 697-715.
73. Yamada, K.M. Adhesive recognition sequences. J. Biol. Chem., 1991, 266, 12809-12812.
74. Ruoslahti, E.; Pierschbacher, M.D. Arg-Gly-Asp: a versatile cell recognition signal. Cell, 1986, 44, 517-518.
75. Curran, M.P.; Keating, G.M. Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Drugs, 2005, 65, 2009-2035.
76. McClellan, K.J.; Goa, K.L. Tirofiban. A review of its use in acute coronary syndromes. Drugs, 1998, 56, 1067-1080.
77. Aumailley, M., Gurrath, M.; Müller, G.; Calvete, J.; Timpl, R.; Kessler, H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett., 1991, 291, 50-54.
78. Haubner, R.; Finsinger, D.; Kessler, H. Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the alpha(V)beta(3) integrin for a new cancer therapy. Ang. Chem. Int. Ed. Engl., 1997, 36, 1375-1389.
79. Dechantsreiter, M.A.; Planker, E.; Matha, B.; Lohof, E.; Holzemann, G.; Jonczyk, A.; Goodmann, S.L.; and Kessler, H. N-Methilated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonist. J. Med. Chem., 1999, 42, 3033-3040.
80. Auzzas, L.; Zanardi, F.; Battistini, L.; Burreddu, P.; Carta, P.; Rassu, G.; Curti, C.; Casiraghi, G. Targeting alphavbeta3 integrin: design and applications of mono-and multifunctional RGD-based peptides and semipeptides. Curr. Med. Chem., 2010, 17, 1255-1299.
81. Paolillo, M.; Russo, M.A.; Serra, M.; Colombo, L.; Schinelli, S. Small molecule integrin antagonists in cancer therapy. Mini Rev. Med. Chem., 2009, 9, 1439-1446.
82. Belvisi, L.; Riccioni, T.; Marcellini, M.; Vesci, L.; Chiarucci, I.; Efrati, D.; Potenza, D.; Scolastico, C.; Manzoni, L.; Lombardo, K.; Stasi, M.A.; Orlandi, A.; Ciucci, A.; Nico, B.; Ribatti, D.; Giannini, G.; Presta, M.; Carminati, P.; Pisano. C. Biological and molecular properties of a new alphavbeta3/alphavbeta5 integrin antagonist. Mol. Cancer Ther., 2005. 4, 1670-1680.
83. Belvisi, L.; Bernardi, A.; Colombo, M.; Manzoni, L.; Potenza, D.; Scolastico, C.; Giannini, G.; Marcellini, M.; Riccioni, T.; Castorina, M.; Logiudice, P.; Pisano, C. Targeting integrins: insights into structure and activity of cyclic RGD pentapeptide mimics containing azabicycloalkane amino acids. Bioorg. Med. Chem., 2006, 14, 169-180.
84. Shannon, K.E.; Keene, J.L.; Settle, S.L.; Duffin, T.D.; Nickols, M.A.; Westlin, M.; Schroeter, S.; Ruminski, P.G.; Griggs, D.W. Anti-metastatic properties of RGD-peptidomimetic agents S137 and S247. Clin. Exp. Metastasis, 2004, 21, 129-138.
85. Marinelli, L.; Meyer, A.; Heckmann, D.; Lavecchia, A.; Novellino, E.; Kessler, H. Ligand binding analysis for human alpha5beta1 integrin: strategies for designing new alpha5beta1 integrin antagonists. J. Med. Chem., 2005, 48, 4204-4207.
86. Tsopanoglou, N.E.; Andriopoulou, P.; Maragoudakis, M.E. On the mechanism of thrombin-induced angiogenesis: involvement of alphavbeta3-integrin. Am. J. Physiol. Cell Physiol., 2002, 283, C1501-C1510.
87. Tsopanoglou, N.E.; Papaconstantinou, M.E.; Flordellis, C.S.; Maragoudakis, M.E. On the mode of action of thrombin-induced angiogenesis: thrombin peptide, TP508, mediates effects in endothelial cells via alphavbeta3 integrin. Thromb. Haemost., 2004, 92, 846-857.
88. Kumar, C.C.; Malkowski, M.; Yin, Z.; Tanghetti, E.; Yaremko, B.; Nechuta, T.; Varner, J.; Liu, M.; Smith, E.M.; Neustadt, B.; Presta, M.; Armstrong, L. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. Cancer Res., 2001, 61, 2232-2238.
89. Meerovitch, K.; Bergeron, F.; Leblond, L.; Grouix, B.; Poirier, C.; Bubenik, M.; Chan, L.; Gourdeau, H.; Bowlin, T.; Attardo, G. A novel RGD antagonist that targets both alphavbeta3 and alpha5beta1 induces apoptosis of angiogenic endothelial cells on type I collagen. Vascul. Pharmacol., 2003, 40, 77-89.
90. Chen, Q.; Manning, C.D.; Millar, H.; McCabe, F.L.; Ferrante, C.; Sharp, C.; Shahied-Arruda, L.; Doshi, P.; Nakada, M.T.; Anderson, G.M. CNTO 95, a fully human anti alphav integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells. Clin. Exp. Metastasis, 2008. 25, 139-148.
91. Trikha, M., Zhou, Z.; Nemeth, J.A.; Chen, Q.; Sharp, C.; Emmell, E.; Giles-Komar, J.; Nakada, M.T. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int. J. Cancer, 2004, 110, 326-335.
92. Martin, P.L.; Jiao, Q.; Cornacoff, J.; Hall, W.; Saville, B.; Nemeth, J.A.; Schantz, A.; Mata, M.; Jang, H.; Fasanmade, A.A.; Anderson, L.; Graham, M.A.; Davis, H.M.; Treacy, G. Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fully human anti-alphav integrin monoclonal antibody, despite widespread tissue binding. Clin. Cancer Res., 2005, 11, 6959-6965.
93. O'Day, S.; Pavlick, A.; Loquai, C.; Lawson, D.; Gutzmer, R.; Richards, J.; Schadendorf, D.; Thompson, J.A.; Gonzalez, R.; Trefzer, U.; Mohr, P.; Ottensmeier, C.; Chao, D.; Zhong, B.; de Boer, C.J.; Uhlar, C.; Marshall, D.; Gore, M.E.; Lang, Z.; Hait, W.; Ho, P. CNTO 95 Investigators. A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br. J. Cancer., 2011, 105, 346-352.
94. Murphy, M.; Cerchio, K.; Stoch, S.; Gottesdiener, K.; Wu, M.; Recker, R. Effect of L-000845704, an αvβ3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J. Clin. Endocrinol. Metab., 2005, 90, 2022-2028.
95. Mattern, R.H.; Read, S.B.; Pierschbacher, M.D.; Sze, C.I.; Eliceiri, B.P.; Kruse C.A. Glioma cell integrin expression and their interactions with integrin antagonists. Cancer Ther., 2005, 3A, 325-340.
96. Stragies, R.; Osterkamp, F.; Zischinsky, G.; Vossmeyer, D.; Kalkhof, H.; Reimer, U.; Zahn, G. Design and synthesis of a new class of selective integrin alpha5beta1 antagonists. J. Med. Chem., 2007, 50, 3786-3794.
97. Mould, A.P.; Askari, J.A.; Aota, S.; Yamada, K.M.; Irie, A.; Takada, Y.; Mardon, H.J.; Humphries, M.J. Defining the topology of integrin α5β1-fibronectin interactions using inhibitory anti-α5 and anti-β1 monoclonal antibodies. J. Biol. Chem., 1997, 272, 17283-17292.
98. Cianfrocca, M.E.; Kimmel, K.A.; Gallo, J.; Cardoso, T.; Brown, M.M.; Hudes, G.; Lewis, N.; Weiner, L.; Lam, G.N.; Brown, S.C.; Shaw, D.E.; Mazar, A.P.; Cohen, R.B. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. Br. J. Cancer., 2006, 94, 1621-1626.
99. Ng, C.M.; Bai, S.; Takimoto, C.H.; Tang, M.T.; Tolcher, A.W. Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-alpha5beta1 integrin monoclonal antibody (volociximab) in cancer patients. Cancer Chemother. Pharmacol., 2010, 65, 207-217.
100. Tilley, J.R. Very late antigen-4 integrin antagonists. Expert Opin. Ther. Pat., 2008, 18, 841-859.
101. Beer, A.J.; Kessler, H.; Wester, H.J.; Schwaiger, M. PET imaging of integrin alphaVbeta3 expression. Theranostics, 2011, 1, 48-57.
102. Schottelius, M.; Laufer, B.; Kessler, H.; Wester, H.J. Ligands for mapping alphavbeta3-integrin expression in vivo. Acc. Chem. Res., 2009, 42, 969-980.
103. Temming, K.; Schiffelers, R.M.; Molema, G.; Kok, R.J. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist. Updat., 2005, 8, 381-402.
104. Axelsson, R.; Bach-Gansmo, T.; Castell-Conesa, J.; McParland, B.J. Study group. An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the alpha v beta 3-selective angiogenesis imaging agent 99mTc-NC100692. Acta Radiol., 2010, 51, 40-46.
105. Kenny, L.M.; Coombes, R.C.; Oulie, I.; Contractor, K.B.; Miller, M., Spinks, T.J.; McParland, B.; Cohen, P.S.; Hui, A.M.; Palmieri, C.; Osman, S.; Glaser, M.; Turton, D.; Al-Nahhas, A.; Aboagye, E.O. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J. Nucl. Med., 2008, 49, 879-886.
106. Laakkonen, P.; Vuorinen, K. Homing peptides as targeted delivery vehicles. Integr. Biol., 2010, 2, 326-337.
107. Arap, W.; Pasqualini, R.; Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 1998, 279, 377-380.
108. De Groot, F.M.H.; Broxterman, H.J.; Adams, H.P.H.M.; van Vliet, A.; Tesser, G.I.; Elderkamp, Y.W.; Schraa, A.J.; Kok, R.J.; Molema, G.; Pinedo, H.M.; Scheeren, H.W. Design, synthesis and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug. Mol. Cancer Ther., 2002, 1, 901-11.
109. Burkhart, D.J.; Kalet, B.T.; Coleman, M.P.; Post, G.C.; Koch, T.H. Doxorubicin-formaldehyde conjugates targeting αvβ3 integrin. Mol. Cancer Ther., 2004, 3, 1593-604.
110. Chen, X.; Plasencia, C.; Hou, Y.; Neamati, N. Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J. Med. Chem., 2005, 48, 1098-1106.
111. Cao, Q.; Li, Z.-B.; Chen, K.; Wu, Z.; He, L.; Neamati, N.; Chen, X. Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide-paclitaxel conjugate in mice with breast cancer. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 1489-1498.
112. Ryppa, C.; Mann-Steinberg, H.; Biniossek, M.L.; Satchi-Fainaro, R.; Kratz, F. In vitro and in vivo evaluation of a paclitaxel conjugate with the divalent peptide E-[c(RGDfK)2] that targets integrin αvβ3. Int. J. Pharm., 2009, 368, 89-97.
113. Ryppa, C.; Mann-Steinberg, H.; Fichtner, I.; Weber, H.; Satchi-Fainaro, R.; Biniossek, M.L.; Kratz, F. In vitro and in vivo evaluation of doxorubicin conjugates with the divalent peptide E-[c(RGDfK)2] that targets integrin αvβ3. Bioconj. Chem., 2008, 19, 1414-1422.
114. Mukhopadhyay, S.; Barnés, C.M.; Haskel, A.; Short, S.M.; Barnes, K.R.; Lippard, S.J. Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature. Bioconj. Chem., 2008, 19, 39-49.
115. Vy as, S.P.; Vaidya, B. Targeted delivery of thrombolytic agents: role of integrin receptors. Expert Opin. Drug Deliv., 2009, 6, 499-508.
116. Manzoni, L.; Belvisi, L.; Arosio, D.; Civera, M.; Pilkington-Miksa, M.; Potenza, D.; Caprini, A.; Araldi, E.M.; Monferini, E.; Mancino, M.; Podestà, F.; Scolastico, C. Cyclic RGD-containing functionalized azabicycloalkane peptides as potent integrin antagonists for tumor targeting. ChemMedChem, 2009, 4, 615-632.
117. Arosio, D.; Manzoni, L.; Araldi, E.M.; Caprini, A.; Monferini, E.; Scolastico, C. Functionalized cyclic RGD peptidomimetics: conjugable ligands for αvβ3 receptor imaging. Bioconjug. Chem., 2009, 20, 1611-1617.
118. 3 integrin in glioblastoma xenografts. Contrast Med. Mol. Imag., 2011, 6, 449-458.
119. Iyer, A.K.; Khaled, G.; Fang, J.; Maeda, H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today, 2006, 11, 812-818.
120. Dreher, M.R.; Liu, W.; Michelich, C.R.; Dewhirst, M.W.; Yuan, F.; Chilkoti, A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J. Natl. Cancer Inst., 2006, 98, 335-344.
121. Zhang, L.; Gu, F.X.; Chan, J.M.; Wang, A.Z.; Langer, R.S.; Farokhzad, O.C. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther., 2008, 83, 761-769.
122. Janib, S.M.; Moses, A.S.; MacKay, J.A. Imaging and drug delivery using theranostic nanoparticles. Adv. Drug Deliv. Rev., 2010, 62, 1052-1063.
123. Xie, J.; Lee, S.; Chen, X. Nanoparticle-based theranostic agents. Adv. Drug Deliv. Rev., 2010, 62, 1064-1079.
124. Ma, X.; Zhao, Y.; Liang, X.J. Theranostic Nanoparticles Engineered for Clinic and Pharmaceutics. Acc. Chem. Res., 2011, 44, 1114-1122.
125. Lammers, T.; Aime, S.; Hennink, W.E.; Storm, G.; Kiessling, F. Theranostic nanomedicines. Acc. Chem. Res., 2011, 44, 1029-1038.
126. st ed.; Taylor & Francis: New York, 2006.
127. Sirsi, S.; Borden, M. Microbubble compositions, properties and biomedical applications. Bubble Sci. Eng. Technol., 2009, 1, 3-17.
128. Lindner, J.R. Molecular imaging of myocardial and vascular disorders with ultrasound. JACC Cardiovasc. Imaging, 2010, 3, 204-211.
129. Ellegala, D.B.; Leong-Poi, H.; Carpenter, J.E.; Klibanov, A.L.; Kaul, S.; Shaffrey, M.E.; Sklenar, J.; Lindner, J.R. Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. Circulation, 2003, 108, 336-341.
130. Leong-Poi, H.; Christiansen, J.; Klibanov, A.L.; Kaul, S.; Lindner, J.R. Noninvasive assessment of angiogenesis by ultrasound and microbubbles targeted to alpha(v)-integrins. Circulation, 2003, 107, 455-460.
131. Leong-Poi, H.; Christiansen, J.; Heppner, P.; Lewis, C.W.; Klibanov, A.L.; Kaul, S.; Lindner, J.R. Assessment of endogenous and therapeutic arteriogenesis by contrast ultrasound molecular imaging of integrin expression. Circulation, 2005, 111, 3248-3254.
132. Tartis, M.S.; McCallan, J.; Lum, A.F.; LaBell, R.; Stieger, S.M.; Matsunaga, T.O.; Ferrara, K.W Therapeutic effects of paclitaxel-containing ultrasound contrast agents. Ultrasound Med. Biol., 2006, 32, 1771-1780.
133. Mufamadi, M.S.; Pillay, V.; Choonara, Y.E.; Du Toit, L.C.; Modi, G.; Naidoo, D.; Ndesendo, V.M.K. A review on composite liposomal technologies for specialized drug delivery. J. Drug. Deliv., 2011, 2011, 939851.
134. Torchilin, V.T. Recent advances with liposomes as pharmameutical carriers. Nat. Rev. drug Discov., 2005, 4, 145-161.
135. Kaasgaard, T.; Andresen, T.L. Liposomal cancer therapy: exploiting tumor characteristics. Expert Opin. Drug Deliv., 2010, 7, 225-243.
136. ® liposomes: from theory to product. Adv. Drug Deliv. Rev., 1997, 24, 165-177.
137. Woodle, M.C. Sterically stabilized liposome therapeutics. Adv. Drug Deliv. Rev., 1995, 16, 249-265.
138. Schiffeler, R.M.; Koning, G.A.; ten Hagen, T.L.M.; Fens, M.H.A.M.; Schraa, A.J.; Janssen, A.P.C.A.; Kok, R.J.; Molema, G.; Storm, G. Antitumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J. Control. Release., 2003, 91, 115-122.
139. Xiong, X.B.; Huang, Y.; Lu, W.L.; Zhang, H.; Nagai, T.; Zhang, Q. Intracellular delivery of doxoribucin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo. J. Pharm. Sci., 2005, 94, 1782-1793.
140. Xiong, X.B.; Huang, Y.; Lu, W.L.; Zhang, X.; Zhang, H.; Nagai, T.; Zhang, Q. Enhanced intracellular delivery and improved antitumor efficacy of doxoribucin by sterically stabilized liposomes modified with a synthetic RGD mimic. J. Control. Release, 2005, 107, 262-275.
141. Hölig, P.; Bach, M.; Völkel, T.; Nahde, T.; Hoffmann, S.; Müller, R.; Kontermann, R.E. Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells. Protein Eng. Des. Sel., 2004, 17, 433-441.
142. Murphy, E.A.; Majeti, B.K.; Barnes, L.A.; Makale, M.; Weis, S.M.; Lutu-Fuga, K.; Wrasidlo, W.; Cheres, D.A. Nanoparticles.mediated drug delivery to tumor vasculature suppressed metastasis. Proc. Natl. Acad. Sci. U.S.A., 2008, 105, 9343-9348.
143. Kurohane, K.; Namba, Y.; Oku, N. Liposomes modified with a synthetic Arg-Gly-Asp mimetic inhibit lung metastasis of B16BL6 melanoma cells. Life Sci., 2000, 68, 273-281.
144. Zhao, H.; Wang, J.C.; Sun, Q.S.; Luo, C.L.; Zhang, Q. RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer. J. Drug. Target., 2009, 17, 10-18.
145. Meng, S.; Su, B.; Li, W.; Ding, Y.; Tang, L.; Zhou, W.; Song, Y.; Li, H.; Zhou, C. Enhanced antitumor effect of novel dual-targeted paclitaxel liposomes. Nantecnology, 2010, 21, 1-7.
146. Dubey, P.K.; Mishra, V.; Jain, S.; Mahor, S.; Vyas, S.P. Liposomes modified with cyclic RGD peptide for tumor targeting. J. Drug. Target., 2004, 12, 257-264.
147. Fens, M.H.; Hill, K.J.; Issa, J.; Ashton, S.E.; Westwood, F.R.; Blakey, D.C.; Storm, G.; Ryan, A.J.; Schiffelers, R.M. Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma. Br. J. Cancer, 2008, 99, 1256-1264.
148. Rapoport, N. Physical stimuli-responsive polymeric micelles for anti-cancer drug delivery. Prog. Polym. Sci., 2007, 32, 962-990.
149. Sutton, D.; Nasongkla, N.; Blanco, E.; Gao, J. Functionalized micellar systems for cancer targeted drug delivery. Pharm. Res., 2007, 24, 1029-1046.
150. Mahmud, M.; Xiong, X.B.; Aliabadi, H.M.; Lavasanifar, A. Polymeric micelles for drug targeting. J. Drug. Target., 2007, 15, 553-584.
151. Oerlemans, C.; Bult, W.; Bos, M.; Storm, G.; Nijsen, J. F.; Hennink, W.E. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm. Res., 2010, 27, 2569-1589.
152. Danson, S.; Ferry, D.; Alakhov, V.; Margison, J.; Kerr, D.; Jowle, D.; Brampton, M.; Halbert, G.; Ranson, M. Phase I dose escalation and pharmacokinetic study of pluronic polymerbound doxorubicin (SP1049C) in patients with advanced cancer. B r. J. Cancer, 2004, 90, 2085-2091.
153. Valle, J.W.; Armstrong, A.; Newman, C.; Alakhov, V.; Pietrzynski, G.; Brewer, J.; Campbell, S.; Corrie, P.; Rowinsky, E.K.; Ranson, M. A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Invest. New Drugs, 2011, 29, 1029-1037.
154. Matsumura, Y.; Hamaguchi, T.; Ura, T.; Muro, K.; Yamada, Y.; Shimada, Y.; Shirao, K.; Okusaka, T.; Ueno, H.; Ikeda, M.; Watanabe, N. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br. J. Cancer, 2004, 91, 1775-1781.
155. Kim, T.Y.; Kim, D.W.; Chung, J.Y.; Shin, S.G.; Kim, S.C.; Heo, D.S.; Kim, N.K.; Bang, Y.J. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelleformulated paclitaxel, in patients with advanced malignancies. Clin. Cancer Res., 2004, 10, 3708-3716.
156. Kim, D.W.; Kim, S.Y.; Kim, H.K.; Kim, S.W.; Shin, S.W.; Kim, J.S.; Park, K.; Lee, M.Y.; Heo, D.S. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann. Oncol., 2007, 18, 2009-2014.
157. Lee, K.S.; Chung, H.C.; Im, S.A.; Park, Y.H.; Kim, C.S.; Kim, S.B.; Rha, S.Y.; Lee, M.Y.; Ro, J. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res. Treat., 2008, 108, 241-250.
158. Nasongkla, N.; Shuai, X.; Ai, H.; Weinberg, B.D.; Pink, J.; Boothman, D.A.; Gao, J. cRGD-functionalized polymer micelles for targeted doxorubicin delivery. Angew. Chem. Int. Ed., 2004, 43, 6323-6327.
159. Nasongkla, N.; Bey, E.; Ren, J.; Ai, H.; Khemtong, C.; Guthi, J.S.; Chin, S.F.; Sherry, A.D.; Boothman, D.A.; Gao, J. Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett., 2006, 6, 2427-2430.
160. Guthi, J.S.; Yang, S.G.; Huang, G.; Li, S.; Khemtong, C.; Kessinger, C.W.; Peyton, M.; Minna, J.D.; Brown, K.C.; Gao, J. MRI-visible micellar nanomedicine for targeted drug delivery to lung cancer cells. Mol. Pharm., 2010, 7, 32-40.
161. Xiong, X.B.; Mahmud, A.; Uludaǧ, H.; Lavasanifar1, A. Multifunctional polymeric micelles for enhanced intracellular delivery of
162. Xiong, X.B.; Ma, Z.; Lai, L.; Lavasanifar, A. The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin. Biomaterials, 2010, 31, 757-768.
163. Hu, Z.; Luo, F.; Pan, Y.; Hou, C.; Ren, L.; Chen, J.; Wang, J.; Zhang, Y. Arg-Gly-Asp (RGD) peptide conjugated poly(lactic acid)-poly(ethylene oxide) micelle for targeted drug delivery. J. Biomed. Mater. Res. A, 2008, 85, 797-807.
164. Yin, J.; Li, Z.; Yang, T.; Wang, J.; Zhang, X.; Zhang, Q. Cyclic RGDyK conjugation facilitates intracellular drug delivery of polymeric micelles to integrin-overexpressing tumor cells and neovasculature. J. Drug Target., 2011, 19, 25-36.
165. Mohanraj, V.J.; Chen, Y. Nanoparticles-a review. Trop. J. Pharm. Res., 2006, 5, 561-573.
166. Harries, M.; Ellis, P; Harper, P. Nanoparticle albumin-bound paclitaxel for metastatic breast cancer. J. Clin. Oncol. 2005, 23, 7768-7771.
167. Danhier, F.; Vroman, B.; Lecouturier, N.; Crokart, N.; Pourcelle, V.; Freichels, H.; Jérôme, C.; Marchand-Brynaert, J.; Feron, O.; Préat V. Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with Paclitaxel. J. Control. Release, 2009, 140, 166-173.
168. Qi, X.; Chen, X.; Sun, Y.; Ma, Z.; Guo, X.; Lu, W.; Duan, Y. Cytotoxicity and cellular uptake evaluation of mitoxantrone-loaded poly(lactic acid-co-lysine) arginine-glycine-aspartic acid nanoparticles. J. App. Polymer Sci., 2011, 119, 1011-1015.
169. Dubey, P.K.; Singodiab, D.; Vermab, R.K.; Vyasc, S.P. RGD modified albumin nanospheres for tumour vasculature targeting. J. Pharm. Pharmacol., 2011, 63, 33-40.
170. Bibby, D.; Talmadge, J.E.; K. Dalal, M.K.; Kurz, S.G.; Chytil, K.M.; Barry, S.E.; Shand, D.G.; Steiert, M. Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice. Int. J. Pharm., 2005, 293, 281-290.
171. Wang, Z.; Chui, W.K.; Ho, P.C. Design of a multifunctional PLGA nanoparticulate drug delivery system: evaluation of its physicochemical properties and anticancer activity to malignant cancer cells. Pharm. Res., 2009, 26, 1162-1171.
172. Wang, Z.; Chui, W.K.; Ho, P.C. Nanoparticulate delivery system targeted to tumor neovasculature for combined anticancer and antiangiogenesis therapy. Pharm. Res., 2011, 28, 585-596.
173. Sugahara, K.N.; Teesalu, T.; Karmali, P.P.; Kotamraju, V.R.; Agemy, L.; Girard, O.M.; Hanahan, D.; Mattrey, R.F.; Ruoslahti, E. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell, 2009, 16, 510-520.
174. Wolinsky, J.B.; Grinstaff, M.W. Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv. Drug Deliv. Rev., 2008, 60, 1037-1055.
175. Medina, S.H.; El-Sayed, M.E.H. Dendrimers as carriers for delivery of chemotherapeutic agents. Chem. Rev., 2009, 109, 3141-3157.
176. Astruc, D.; Boisselier, E.; Ornelas, C. Dendrimers designed for functions: from physical, photophysical, and supramolecular properties to applications in sensing, catalysis, molecular electronics, photonics, and nanomedicine. Chem. Rev. 2010, 110, 1857-1959.
177. Shukla, R.; Thomas, T.P.; Peters, J.; Kotlyar, A.; Myc, A.; Baker, J.J.R. Tumor angiogenic vasculature targeting with PAMAM dendrimer-RGD conjugates. Chem. Commun., 2005, 14, 5739-5741.
178. Dijkgraar, I.; Kruijtzer, J.A.W.; Liu, S.; Soede, A.C.; Oyen, W.J.G.; Corstens, F.H.M.; Liskamp, R.M.J.; Boerman, O.C. Improved targeting of the αvβ3 integrin by multimerisation of RGD peptides. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, 267-273.
179. Dijkgraar, I.; Rijnders, A.Y.; Soede, A.; Dechesne, A.C.; van Esse, G.W.; Brouwer A.J.; Corstens, F.H.M.; Boerman, O.C.; Rijkers, D.T.S.; Liskamp, R.M.J. Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1.3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes. Org. Biomol. Chem., 2007, 5, 935-944.
180. 111In-labeled RGD peptide. Nucl. Med. Biology, 2007, 34, 29-35.
181. 3 expression in living mice. Bioconjugate Chem., 2005, 16, 1433-1441.
182. 3 integrin expression. J. Nucl. Med., 2007, 48, 1162-1171.
183. 3 targeted radiotracers for tumor imaging. Mol. Pharm., 2006, 3, 472-487.
184. Zhu, S.; Qian, L.; Hong, M.; Zhang, L.; Pei, Y.; Jiang, Y. RGD-modified PEG-PAMAM-DOX conjugate: in vitro and in vivo targeting to both tumor neovascular endothelial cells and tumor cells. Adv. Mater., 2011, 23, H84-H89.
185. Wei, W.; Sethuraman, A.; Jin, C.; Monteiro-Riviere, N.A.; Narayan, R.J. Biological properties of carbon nanotubes. J Nanosci. Nanotechnol., 2007, 7, 1284-1297.
186. Prato, M.; Kostarelos, K.; Bianco, A. Functionalized carbon nanotubes in drug design and discovery. Acc. Chem. Res., 2008, 41, 60-68.
187. Bianco, A.; Kostarelo, K.; Prato, M. Applications of carbon nanotubes in drug delivery. Curr. Opin. Chem. Biol., 2005, 9, 674-679.
188. Ji, S.; Liu, C.; Zhang, B.; Yang, F.; Xu, J.; Long, J.; Jin, C.; Fu, D.; Ni, Q.; Yu, X. Carbon nanotubes in cancer diagnosis and therapy. Biochim. Biophys. Acta, 2010, 1806, 29-35.
189. Oberdörster, G. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. J. Intern. Med., 2010, 267, 89-105.
190. Firme, C.P.3rd; Bandaru, P.R. Toxicity issues in the application of carbon nanotubes to biological systems. Nanomedicine, 2010, 6, 245-256.
191. Tasis, D.; Tagmatarchis, N.; Bianco, A.; Prato, M. Chemistry of carbon nanotubes. Chem. Rev., 2006, 106, 1105-1136.
192. Liu, Z.; Cai, W.; He, L.; Nakayama, N.; Chen, K.; Sun, X.; Chen, X.; Dai, H. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat. Nanotechnol., 2007, 2, 47-52.
193. Liu, Z.; Sun, X.; Nakayama-Ratchford, N.; Dai, H. Supramolecular chemistry on water-soluble carbon nanotubes for drug loading and delivery. ACS Nano, 2007, 1, 50-56.
194. Sperling, R.A.; Rivera Gil, P.; Zhang, F.; Zanella, M.; Parak, W.J. Biological applications of gold nanoparticles. Chem. Soc. Rev., 2008, 37, 1896-1908.
195. Boisselier, E.; Astruc, D. Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. Chem. Soc. Rev., 2009, 38, 1759-1782.
196. Arvizo, R.; Bhattacharya, R.; Mukherjee, P. Gold nanoparticles: opportunities and challenges in nanomedicine. Expert Opin. Drug Deliv., 2010, 7, 753-763.
197. Corot, C.; Robert, P.; Idée, J.M.; Port, M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv. Drug Deliv. Rev., 2006, 58, 1471-1504.
198. Laurent, S.; Forge, D.; Port, M.; Roch, A.; Robic, C.; Vander Elst, L.; Muller, R.N. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem. Rev. 2008, 108, 2064-2110.
199. Jun, Y.; Lee, J.-H.; Cheon, J. Chemical design of nanoparticle probes for high-performance magnetic resonance imaging. Angew. Chem. Int. Ed., 2008, 47, 5122-5135.
200. Cheon, J.; Lee, J.H. Synergically integrated nanoparticles as multimodal probes for nanobiotechnology. Acc. Chem. Res., 2008, 41, 1630-1640.
201. Gao, X.; Yang, L.; Petros, J.A.; Marshall, F.F.; Simons, J.W.; Nie, S. In vivo molecular and cellular imaging with quantum dots. Curr. Opin. Biotechnol., 2005 16, 63-72.
202. Smith, A.M.; Duan, H.; Mohs, A.M.; Nie, S. Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv. Drug Deliv. Rev., 2008, 60, 1226-1240.
203. Cai, W.; Chen, X. Nanoplatforms for targeted molecular imaging in living subjects. Small, 2007, 3, 1840-1854.
204. Wang, C.; Gao, X.; Su, X. In vitro and in vivo imaging with quantum dots. Anal. Bioanal. Chem. 2010, 397, 1397-1415.
205. Cherukuri, P.; Glazer, E.S.; Curley, S.A. Targeted hyperthermia using metal nanoparticles. Adv. Drug. Deliv. Rev., 2010, 62, 339-345.
206. Kievit, F.M.; Zhang, M. Surface engineering of iron oxide nanoparticles for targeted cancer therapy. Acc. Chem. Res., 2011, 44, 853-862.
207. Ghosh, P. Han, G.; De, M.; Kim, C.K.; Rotello, V.M. Gold nanoparticles in delivery applications. Adv. Drug Deliv. Rev., 2008, 60, 1307-1315.
208. Qi, L.; Gao, X. Emerging application of quantum dots for drug delivery and therapy. Expert Opin. Drug Deliv., 2008, 5, 263-267.
209. Montet, X.; Funovics, M.; Montet-About, K.; Weissleder, R.; Josephson, L. Multivalent effects of RGD peptides obtained by nanoparticle dispay. J. Med. Chem., 2006, 49, 6087-6093.
210. 3-rich tumor cells. J. Am. Chem. Soc., 2008, 130, 7542-7543.
211. Zhang, C.; Jugold, M.; Woenne, E.C.; Lammers, T.; Morgenstern, B.; Mueller, M.M.; Zentgraf, H.; Bock, M.; Eisenhut, M.; Semmler, W.; Kiessling, F. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res., 2007, 67, 1555-1562.
212. Chen, K.; Xie, J.; Xu, H.; Behera, D.; Michalski, M.H.; Biswal, S.; Wang, A.; Chen, X. Triblock copolymer coated iron oxide nanoparticle conjugate for tumor integrin targeting. Biomaterials, 2009, 30, 6912-6919.
213. Lee, H.-Y.; Li, Z.; Chen, K.; Hsu, A.R.; Xu, C.; Xie, J.; Sun, S.; Chen. X. PET/MRI dual-modality tumor imaging using Arginine-Glycine-Aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J. Nucl. Med., 2008, 49, 1371-1379.
214. Xie, J.; Chen, K.; Huang, J.; Lee, S.; Wang, J.; Gao, J.; Li, X.; Chen, X. PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials, 2010, 31, 3016-3022.
215. Yu, M.K.; Park, J.; Jeong, Y.Y.; Moon, W.K.; Jon, S. Integrin-targeting thermally cross-linked superparamagnetic iron oxide nanoparticles for combined cancer imaging and drug delivery. Nanotechnology, 2010, 21, 415102-415111.
216. 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials, 2011, 32, 4151-4160.
217. Gibson, J.D.; Khanal, B.P.; Zubarev, E.R. Paclitaxel-functionalized gold nanoparticles. J. Am. Chem. Soc., 2007, 129, 11653-11661.
218. Zhang, X.; Chibli, H.; Mielke, R.; Nadeau, J. Ultrasmall gold-doxorubicin conjugates rapidly kill apoptosis-resistant cancer cells. Bioconjugate Chem., 2011, 22, 235-243.
219. Wang, F.; Wang, Y.C.; Dou, S.; Xiong, M.H.; Sun, T.M.; Wang, J. Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. ACS Nano, 2011, 5, 3679-3692.
220. Li, Z.; Huang, P.; Zhang, X.; Lin, J.; Yang, S.; Liu, B.; Gao, F.; Xi, P.; Ren, Q.; Cui, D. RGD-conjugated dendrimer-modified gold nanorods for in Vivo tumor targeting and photothermal therapy. Mol. Pharm., 2010, 7, 94-104.
221. Arosio, D.; Manzoni, L. Araldi, E. M.; Scolastico, C. Cyclic RGD functionalized gold nanoparticles for tumor targeting. Bioconjug. Chem., 2011, 22, 664-672.
222. Chen, N.; He, Y.; Su, Y.; Li, X.; Huang, Q.; Wang, H.; Zhang, X.; Tai, R.; Fan, C. The cytotoxicity of cadmium-based quantum dots. Biomaterials, 2012, 33, 1238-1244.
223. Kirchner, C.; Liedl, T.; Kudera, S.; Pellegrino, T.; Javier, A.M.; Gaub, H.E.; Stolzle, S.; Fertig, N.; Parak, W.J. Cytotoxicity of colloidal CdSe and CdSe/ZnS nanoparticles. Nano Lett., 2005, 5, 331-338.
224. Cai, W.B.; Shin, D.W.; Chen, K.; Gheysens, O.; Cao, Q.Z.; Wang, S.X.; Gambhir, S.S.; Chen, X.Y. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects, Nano Lett., 2006, 6, 669-676.
225. Yong, K.-T.; Roy, I.; Lawb, W.-C.; Hub, R. Synthesis of cRGD-peptide conjugated near-infrared CdTe/ZnSe core-shell quantum dots for in vivo cancer targeting and imaging. Chem. Commun., 2010, 46, 7136-7138.
226. Gao, J.; Chen, K.; Xie, R.; Xie, J.; Yan, Y.; Cheng, Z.; Peng, X.; Chen, X. In vivo tumor-targeted fluorescence imaging using near-infrared non-cadmium quantum dots. Bioconjug. Chem., 2010, 21, 604-609.
227. Atmaja, B.B.; Lui, B.H.; Hu, Y.; Beck, S.E.; Frank, C.W.; Cochran, J.R. Targeting of cancer cells using quantum dot-polypeptide hybrid assemblies that function as molecular imaging agents and carrier systems. Adv. Funct. Mater., 2010, 20, 4091-4097.
228. Hood, J.D.; Bednarski, M.; Frausto, R.; Guccione, S.; Reisfeld, R.A.; Xiang, R.; Cheresh, D.A. Tumor regression by targeted gene delivery to the neovasculature. Science, 2002, 296, 2404-2407.
229. Wagner, E.; Kircheis, R.; Walker, G.F. Targeted nucleic acid delivery into tumors: new avenues for cancer therapy. Biomed. Pharmacother., 2004, 58, 152-161.
230. Schiffelers, R.M.; Ansari, A.; Xu, J.; Zhou, Q.; Tang, Q.; Storm, G.; Molema, G.; Lu, P.Y.; Scaria, P.V.; Woodle, M.C. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res., 2004, 32, e149.
231. Waite, C.L.; Roth, CM. PAMAM-RGD conjugates enhance siRNA delivery through a multicellular spheroid model of malignant glioma. Bioconjug. Chem., 2009, 20, 1908-1916.
232. Han, H.D.; Mangala, L.S.; Lee, J.W.; Shahzad, M.M.; Kim, H.S.; Shen, D.; Nam, E.J.; Mora, E.M.; Stone, R.L.; Lu, C.; Lee, S.J.; Roh, J.W.; Nick, A.M.; Lopez-Berestein, G.; Sood, A.K. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin. Cancer Res., 2010, 16, 3910-3922.
233. Xiong, X.B.; Uludaǧ, H.; Lavasanifar, A. Virus-mimetic polymeric micelles for targeted siRNA delivery. Biomaterials., 2010, 31, 5886-5893.
234. Xiong, X.B.; Lavasanifar, A. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. ACS Nano, 2011, 5, 5202-5213.
235. Pasqualini, R.; Ruoslahti, E. Organ targeting in vivo using phage display peptide libraries. Nature, 1996, 380, 364-366.
236. Zhou, J.; Wu, J.; Hafdi, N.; Behr, J.P.; Erbacher, P.; Peng, L. PAMAM dendrimers for efficient siRNA delivery and potent gene silencing. Chem. Commun. (Camb.), 2006, 22, 2362-2364.
237. Kaneshiro, T.L.; Lu, Z.R. Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. Biomaterial, 2009, 30, 5660-5666.
238. Winter, P.M.; Caruthers, S.D.; Kassner, A.; Harris, T.D.; Chinen L.K.; Allen, J.S.; Lacy, E.K.; Zhang, H.; Robertson, J.D.; Wickline, S.A.; Lanza, G.M. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res., 2003, 63, 5838-5843.
239. Winter, P.M.; Morawski, A.M.; Caruthers, S.D.; Fuhrhop, R.W.; Zhang, H.; Williams, T.A.; Allen, J.S.; Lacy, E.K.; Robertson, J.D.; Lanza, G.M.; Wickline, S.A. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation, 2003, 108, 2270-2274.
240. Winter, P.M.; Neubauer, A.M.; Caruthers, S.D.; Harris, T.D.; Robertson, J.D.; Williams, T.A.; Schmieder, A.H.; Hu, G.; Allen, J.S.; Lacy, E.K.; Zhang, H.; Wickline, S.A.; Lanza, G.M. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2006, 26, 2103-2109.
241. Winter, P.M.; Caruthers, S.D.; Zhang, H.; Williams, T.A.; Wickline, S.A.; Lanza, G.M. Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JACC Cardiovasc. Imaging, 2008, 1, 624-634.
242. Winter, P.M.; Schmieder, A.H.; Caruthers, S.D.; Keene, J.L.; Zhang, H.; Wickline, S.A.; Lanza, G.M. Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits. FASEB J., 2008, 22, 2758-2767.
243. Meoli, D.F.; Sadeghi, M.M.; Krassilnikova, S.; Bourke, B.N.; Giordano, F.J.; Dione, D.P.; Su, H.; Edwards, D.S.; Liu, S.; Harris, T.D.; Madri, J.A.; Zaret, B.L.; Sinusas, A.J. Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J. Clin. Invest., 2004, 113, 1684-1691.
244. Kalinowski, L.; Dobrucki, L.W.; Meoli, D.F.; Dione, D.P.; Sadeghi, M.M.; Madri, J.A.; Sinusas, A.J. Targeted imaging of hypoxia-induced integrin activation in myocardium early after infarction. J. Appl. Physiol., 2008, 104, 1504-1512.
245. Dobrucki, L.W.; Dione, D.P.; Kalinowski, L.; Dione. D.; Mendizabal, M.; Yu, J.; Papademetris, X.; Sessa, W.C.; Sinusas, A.J. Serial noninvasive targeted imaging of peripheral angiogenesis: validation and application of a semiautomated quantitative approach. J. Nucl. Med., 2009, 50, 1356-1363.
246. Sadeghi, M.M.; Krassilnikova, S.; Zhang, J.; Gharaei, A.A.; Fassaei, H.R.; Esmailzadeh, L.; Kooshkabadi, A.; Edwards, S.; Yalamanchili, P.; Harris, T.D.; Sinusas, A.J.; Zaret, B.L.; Bender, J.R. Detection of injury-induced vascular remodeling by targeting activated alphavbeta3 integrin in vivo. Circulation, 2004, 110, 84-90.
247. Zhang, J.; Krassilnikova, S.; Gharaei, A.A.; Fassaei, H.R.; Esmailzadeh, L.; Asadi, A.; Edwards, D.S.; Harris, T.D.; Azure, M.; Tellides, G.; Sinusas, A.J.; Zaret, B.L.; Bender, J.R.; Sadeghi, M.M. Alphavbeta3-targeted detection of arteriopathy in transplanted human coronary arteries: an autoradiographic study. FASEB J., 2005, 19, 1857-1859.
248. 68Ga-NOTA cyclic RGD peptide for alphavbeta3 integrin imaging after myocardial infarction in small animal by PET/CT, Proceedings of EANM'10 Annual congress of the European Association of Nuclear Medicine, Vienna, Austria, October 9-13, 2010.
249. Haukkala, J.; Laitinen, I.; Luoto, P.; Iveson, P.; Wilson, I.; Karlsen, H.; Cuthbertson, A.; Laine, J.; Leppänen, P.; Ylä-Herttula, S.; Knuuti, J.; Roivainen, A. 68Ga-DOTA-RGD peptide: biodistribution and binding into atherosclerotic plaques in mice. Eur. J. Nucl. Med. Mol. Imaging, 2009, 36, 2058-2067.
250. Dai, W.; Yang, T.; Wang, X.; Wang, J.; Zhang, X.; Zhang, Q. PHSCNK-modified and doxorubicin loaded liposomes as a dual targetind system to integrin-overexpressing tumor neovascolature and tumor cells. J. Drug Target., 2010, 18, 254-263.
251. Demirgöz, D.; Garg, A.; Kokkoli, E. PR-b-targeted PEGylated liposomes for prostate cancer therapy. Langmuir, 2008, 24, 13518-13524.
252. Schmieder, A.H:, Caruthers, S.D.; Zhang, H.; Williams, T.A.; Robertson, J.D.; Wickline, S.A.; Lanza, G.M. Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model. FASEB J., 2008, 22, 4179-4189.
253. McCarthy, J.R. Nanomedicine and Cardiovascular Disease. Curr. Cardiovasc. Imaging. Rep., 2010, 3, 42-49.
254. Lindsay, A.C.; Choudhury, R.P. Form to function: current and future roles of atherosclerosis imaging in drug discovery. Nat. Rev. Drug Discov. 2008, 7, 517-529.
255. Charo, I.F. Taub, R. Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat. Rev Drug Discov., 2011, 10, 365-376.
256. McAteer, M.A.; Akhtar, A.M.; von Zur Muhlen, C.; Choudhury, R.P. An approach to molecular imaging of atherosclerosis, thrombosis, and vascular inflammation using microparticles of iron oxide. Atherosclerosis, 2010, 209, 18-27.
257. Wang, X.T.; Li, S.; Zhang, X.B.; Hou, X.P. Preparation of thrombus-targeted urokinase liposomes and its thrombolytic effect in model rats. Yao Xue Xue Bao, 2003, 38, 231-235.
258. Wang, S.S.; Chou, N.K.; Chung, T.W. The t-PA-encapsulated PLGA nanoparticles shelled with CS or CS-GRGD alter both permeation through and dissolving patterns of blood clots compared with t-PA solution: an in vitro thrombolysis study. J. Biomed. Mater. Res. A, 2009, 91, 753-761.
259. Chung, T.W.; Wang, S.S.; Tsai, W.J. Accelerating thrombolysis with chitosan-coated plasminogen activators encapsulated in poly-(lactide-co- glycolide) (PLGA) nanoparticles. Biomaterials, 2008, 29, 228-237.
260. Huang, G.; Zhou, Z.; Srinivasan, R.; Penn, M.S.; Kottke-Marchant, K.; Marchant, R.E.; Gupta, A.S. Affinity manipulation of surface-conjugated RGD peptide to modulate binding of liposomes to activated platelets. Biomaterials, 2008, 29, 1676-1685.
261. Srinivasan, R.; Marchant, R.E.; Gupta, A.S. In vitro and in vivo platelet targeting by cyclic RGD-modified liposomes. J. Biomed. Mater. Res., 2010, 93, 1004-1015.
262. Garcia-Gila, M.; Cabanas, C.; Garcia-Pardo, A. Analysis of the activation state of alpha4beta1 integrin in human B cell lines derived from myeloma, leukemia or lymphoma. FEBS Lett., 1997, 418, 337-340.
263. Zhong, S.; Bhattacharya, S.; Chan, W.; Jasti, B.; Li, X. Leucine-Aspartic Acid-Valine sequence as targeting ligand and drug carrier for doxorubicin delivery to melanoma cells: in vitro cellular uptake and cytotoxicity studies. Pharm Res., 2009, 26, 2578-2587.
264. Tsourkas, A.; Shinde-Patil, V.R.; Kelly, K.A.; Patel, P.; Wolley, A.; Allport, J.R.; Weissleder, R. In vivo imaging of activated endothelium using an anti-VCAM-1 magnetooptical probe. Bioconjug. Chem., 2005, 16, 576-581.
265. McAteer, M.A.; Schneider, J.E.; Ali, Z.A.; Warrick, N.; Bursill, C.A.; von zur Muhlen, C.; Greaves, D.R.; Neubauer, S.; Channon, K.M.; Choudhury, R.P. Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual-targeted microparticles of iron oxide. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 77-83.
266. Kaufmann, B.A.; Sanders, J.M.; Davis, C.; Xie, A.; Aldred, P.; Sarembock, I.J.; Lindner, J.R Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1. Circulation, 2007, 116, 276-284.
267. Behm, C.Z.; Kaufmann, B.A.; Carr, C.; Lankford, M.; Sanders, J.M.; Rose, C.E.; Kaul, S.; Lindner, J.R. Molecular imaging of endothelial vascular cell adhesion molecule-1 expression and inflammatory cell recruitment during vasculogenesis and ischemia-mediated arteriogenesis. Circulation, 2008, 117, 2902-2911.
268. Weller, G.E.; Lu, E.; Csikari, M.M.; Klibanov, A.L.; Fischer, D.; Wagner, W.R.; Villanueva, F.S. Ultrasound imaging of acute cardiac transplant rejection with microbubbles targeted to ICAM-1 (intercellular adhesion molecule-1). Circulation, 2003; 108, 218-224.
269. Villanueva, F.S.; Jankowski, R.J.; Klibanov, S.; Pina, M.L.; Alber, S.M.; Watkins, S.C. Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells. Circulation, 1998, 98, 1-5.
270. Shimaoka, M.; Springer, T.A. Therapeutic antagonists and conformational regulation of integrin function. Nat. Rev. Drug Discov., 2003, 2, 703-716.
271. Yusuf-Makagiansar, H.; Siahaan, T.J. Binding and internalization of an LFA-1-derived cyclic peptide by ICAM receptors on activated lymphocyte: a potential ligand for drug targeting to ICAM-1-expressing cells. Pharm. Res., 2001, 18, 329-335.
272. Chittasupho, C.; Xie, S.X.; Baoum, A.; Yakovleva, T.; Siahaan, T.J.; Berkland, C.J. ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells. Eur. J. Pharm. Sci., 2009, 37, 141-150.
273. Jones, L.S. Integrins: possible functions in the adult CNS. Trends Neurosci., 1996, 19, 68-72.
274. Milner, R.; Campbell, I.L. The integrin family of cell adhesion molecules has multiple functions within the CNS. J. Neurosci. Res., 2002, 69, 286-291.
275. Clegg, D.O.; Wingerd, K.L.; Hikita, S.T.; Tolhurst, E.C. Integrins in the development, function and dysfunction of the nervous system. Front. Biosci., 2003, 8, d723-d750.
276. Su, L.; Lv, X.; Miao, J. Integrin beta 4 in neural cells. Neuromolecular Med., 2008, 10, 316-321.
277. Campos, L.S. Beta1 integrins and neural stem cells: making sense of the extracellular environment. Bioessays, 2005, 27, 698-707.
278. Olivier, J.C. Drug transport to brain with target nanoparticles. NeuroRx, 2005, 2, 108-119.
279. Béduneau, A.; Saulnier, P.; Benoit, J.P. Active targeting of brain tumors using nanocarriers. Biomaterials, 2007, 28, 4947-4967.
280. Archelos, J.J.; Previtali, S.C.; Hartung, H.P. The role of integrins in immunemediated diseases of the nervous system. Trends Neurosci., 1999, 22, 30-38.
281. del Zoppo, G.J.; Milner, R. Integrin-matrix interactions in the cerebral microvasculature. Arterioscler. Thromb. Vasc. Biol., 2006, 26, 1966-1975.
282. Desai, B.S.; Monahan, A.J.; Carvey, P.M.; Hendey, B. Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy. Cell Transplant., 2007, 16, 285-299.
283. Cuenca-López, M.D.; Brea, D.; Segua, T.; Galindo, M.F.; Antón-Martínez, D.; Sanz, M.J.; Agulla, J.; Castillo, J.; Jordán, J. Inflammation as a therapeutic agent in cerebral infarction: cellular inflammatory response and inflammatory mediators. Rev. Neurol., 2010, 50, 349-359
284. McAteer, M.A.; Sibson, N.R.; von Zur Muhlen, C.; Schneider, J.E.; Lowe, A.S.; Warrick, N.; Channon, K.M.; Anthony, D.C.; Choudhury, R.P. In vivo magnetic resonance imaging of acute brain inflammation using microparticles of iron oxide. Nat. Med., 2007, 13, 1253-1258.
285. Yan, H.; Wang, L.; Wang, J.; Weng, X.; Lei, H.; Wang, X.; Jiang, L.; Zhu, J.; Lu, W.; Wei, X.; Li, C. Two-order targeted brain tumor imaging by using an optical/paramagnetic nanoprobe across the blood brain barrier. ACS Nano, 2012, 6, 410-420.
286. Demeule, M.; Regina, A.; Che, C.; Poirier, J.; Nguyen, T.; Gabathuler, R.; Castaigne, J. P.; Beliveau, R. Identification and design of peptides as a new drug delivery system for the brain. J. Pharmacol. Exp. Ther., 2008, 324, 1064-1072.
287. Hynynen, K. Ultrasound for drug and gene delivery to the brain. Adv. Drug Deliv. Rev., 2008, 60, 1209-1217.
288. Ting, C.Y.; Fan, C.H.; Liu, H.L.; Huang, C.Y.; Hsieh, H.Y.; Yen, T.C.; Wei, K.C.; Yeh, C.K. Concurrent blood-brain barrier opening and local drug delivery using drug-carrying microbubbles and focused ultrasound for brain glioma treatment. Biomaterials, 2012, 33, 704-712.